Literature DB >> 19091301

Pharmacotherapy for adults with tumors of the central nervous system.

Nina F Schor1.   

Abstract

Tumors of the adult central nervous system are among the most common and most chemoresistant neoplasms. Malignant tumors of the brain and spinal cord collectively account for approximately 1.3% of all cancers and 2.2% of all cancer-related deaths. Novel pharmacological approaches to nervous system tumors are urgently needed. This review presents the current approaches and challenges to successful pharmacotherapy of adults with malignant tumors of the central nervous system and discusses novel approaches aimed at overcoming these challenges.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19091301      PMCID: PMC2782733          DOI: 10.1016/j.pharmthera.2008.11.003

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  129 in total

1.  In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.

Authors:  Ioannis A Avramis; Garyfallia Christodoulopoulos; Atsushi Suzuki; Walter E Laug; Ignacio Gonzalez-Gomez; George McNamara; Edward A Sausville; Vassilios I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  2002-10-17       Impact factor: 3.333

2.  Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.

Authors:  Lucio Tentori; Ilaria Portarena; Francesco Torino; Massimo Scerrati; Pierluigi Navarra; Grazia Graziani
Journal:  Glia       Date:  2002-10       Impact factor: 7.452

3.  The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.

Authors:  John R Silber; Michael S Bobola; A Blank; Kathryn D Schoeler; Peter D Haroldson; Mary B Huynh; Douglas D Kolstoe
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

4.  Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.

Authors:  Raymond I Haroun; Richard E Clatterbuck; M Christopher Gibbons; Peter C Burger; Ricardo Parker; John P Fruehauf; Henry Brem
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

5.  Multifaceted resistance of gliomas to temozolomide.

Authors:  Dora B Bocangel; Sydney Finkelstein; S Clifford Schold; Kishor K Bhakat; Sankar Mitra; Demetrius M Kokkinakis
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

6.  Adenoviral transfer of antisenses or ribozyme to O6-methylguanine-DNA methyltransferase mRNA in brain-tumor model resistant to chloroethyl-nitrosourea.

Authors:  Yoshinobu Manome; Hisao Yoshinaga; Michiko Watanabe; Tsuneya Ohno
Journal:  Anticancer Res       Date:  2002 Jul-Aug       Impact factor: 2.480

Review 7.  Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.

Authors:  Guido Reifenberger; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2003-02       Impact factor: 3.685

8.  Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis.

Authors:  Manuela Reichert; Joachim P Steinbach; Petra Supra; Michael Weller
Journal:  Cancer       Date:  2002-09-01       Impact factor: 6.860

9.  Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells.

Authors:  Patrick Guensberg; Volker Wacheck; Trevor Lucas; Brett Monia; Hubert Pehamberger; Hans-Georg Eichler; Burkhard Jansen
Journal:  Chemotherapy       Date:  2002-09       Impact factor: 2.544

Review 10.  Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update.

Authors:  Fateme Salehi; Kalman Kovacs; Bernd W Scheithauer; Ricardo V Lloyd; Michael Cusimano
Journal:  Endocr Relat Cancer       Date:  2008-09       Impact factor: 5.678

View more
  5 in total

Review 1.  Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors.

Authors:  Hemant Sarin
Journal:  Ther Deliv       Date:  2010-08

Review 2.  Elucidating immunometabolic targets in glioblastoma.

Authors:  Pooja Agarwal; Michael J Pajor; David M Anson; Maheedhara R Guda; Collin M Labak; Andrew J Tsung; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

3.  Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression.

Authors:  Antonella Calogero; Antonio Porcellini; Vincenza Lombari; Cinzia Fabbiano; Antonietta Arcella; Massimo Miscusi; Donatella Ponti; Giuseppe Ragona
Journal:  Cancer Cell Int       Date:  2011-03-02       Impact factor: 5.722

Review 4.  Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS).

Authors:  Marta Lukaszewicz-Zając; Barbara Mroczko; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2013-12-24       Impact factor: 3.575

Review 5.  Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.

Authors:  Marianela Candolfi; Kurt M Kroeger; A K M G Muhammad; Kader Yagiz; Catherine Farrokhi; Robert N Pechnick; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.